Free Trial

Acumen Pharmaceuticals (ABOS) Competitors

Acumen Pharmaceuticals logo
$2.33 +0.21 (+9.91%)
Closing price 10/14/2025 04:00 PM Eastern
Extended Trading
$2.29 -0.04 (-1.67%)
As of 04:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ABOS vs. ALMS, ETHZ, LRMR, ACIU, FDMT, ENGN, KMDA, YMAB, AMRN, and TVRD

Should you be buying Acumen Pharmaceuticals stock or one of its competitors? The main competitors of Acumen Pharmaceuticals include Alumis (ALMS), Flag Ship Acquisition (ETHZ), Larimar Therapeutics (LRMR), AC Immune (ACIU), 4D Molecular Therapeutics (FDMT), enGene (ENGN), Kamada (KMDA), Y-mAbs Therapeutics (YMAB), Amarin (AMRN), and Tvardi Therapeutics (TVRD). These companies are all part of the "pharmaceutical products" industry.

Acumen Pharmaceuticals vs. Its Competitors

Alumis (NASDAQ:ALMS) and Acumen Pharmaceuticals (NASDAQ:ABOS) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, media sentiment, profitability, dividends, analyst recommendations, risk, valuation and institutional ownership.

Acumen Pharmaceuticals' return on equity of -81.39% beat Alumis' return on equity.

Company Net Margins Return on Equity Return on Assets
AlumisN/A -119.15% -92.50%
Acumen Pharmaceuticals N/A -81.39%-61.96%

Alumis presently has a consensus price target of $20.17, indicating a potential upside of 335.57%. Acumen Pharmaceuticals has a consensus price target of $7.00, indicating a potential upside of 200.43%. Given Alumis' stronger consensus rating and higher possible upside, research analysts clearly believe Alumis is more favorable than Acumen Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Alumis
1 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
2.89
Acumen Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.60

In the previous week, Alumis had 1 more articles in the media than Acumen Pharmaceuticals. MarketBeat recorded 4 mentions for Alumis and 3 mentions for Acumen Pharmaceuticals. Alumis' average media sentiment score of 1.09 beat Acumen Pharmaceuticals' score of 0.83 indicating that Alumis is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Alumis
1 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Acumen Pharmaceuticals
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AlumisN/AN/A-$294.23MN/AN/A
Acumen PharmaceuticalsN/AN/A-$102.33M-$2.28-1.02

71.0% of Acumen Pharmaceuticals shares are held by institutional investors. 40.7% of Alumis shares are held by insiders. Comparatively, 7.1% of Acumen Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Alumis has a beta of -1.47, indicating that its stock price is 247% less volatile than the S&P 500. Comparatively, Acumen Pharmaceuticals has a beta of 0.2, indicating that its stock price is 80% less volatile than the S&P 500.

Summary

Alumis beats Acumen Pharmaceuticals on 7 of the 12 factors compared between the two stocks.

Get Acumen Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for ABOS and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ABOS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ABOS vs. The Competition

MetricAcumen PharmaceuticalsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$128.42M$3.35B$6.04B$10.50B
Dividend YieldN/A2.30%5.73%4.80%
P/E Ratio-1.0221.9084.6427.24
Price / SalesN/A263.81508.12197.88
Price / CashN/A46.9537.5761.53
Price / Book0.7710.4312.256.74
Net Income-$102.33M-$52.58M$3.32B$276.59M
7 Day Performance23.94%-1.55%-1.34%-0.47%
1 Month Performance84.92%12.96%8.14%7.47%
1 Year PerformanceN/A15.43%72.27%34.58%

Acumen Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ABOS
Acumen Pharmaceuticals
3.2592 of 5 stars
$2.33
+9.9%
$7.00
+200.4%
-0.9%$128.42MN/A-1.0220News Coverage
Analyst Forecast
ALMS
Alumis
3.564 of 5 stars
$4.12
+2.5%
$20.17
+389.5%
-55.1%$418.34MN/A0.00N/ANews Coverage
ETHZ
Flag Ship Acquisition
N/A$2.55
+0.8%
N/AN/A$416.01MN/A-0.177Gap Up
LRMR
Larimar Therapeutics
2.9404 of 5 stars
$4.81
-1.2%
$16.71
+247.5%
-46.2%$403.13MN/A-3.0830
ACIU
AC Immune
1.7761 of 5 stars
$3.54
-11.3%
$10.00
+182.5%
-3.8%$400.64M$28.92M-6.10140High Trading Volume
FDMT
4D Molecular Therapeutics
2.4415 of 5 stars
$8.40
-1.8%
$30.40
+261.9%
+10.4%$399.31M$40K-2.38120News Coverage
ENGN
enGene
2.7482 of 5 stars
$7.60
-1.9%
$19.50
+156.6%
+14.1%$396.74MN/A-4.0031Trending News
Analyst Forecast
Gap Up
KMDA
Kamada
4.4812 of 5 stars
$6.70
-1.8%
$13.00
+94.0%
+29.4%$392.18M$160.95M19.71360News Coverage
YMAB
Y-mAbs Therapeutics
1.2885 of 5 stars
$8.61
flat
$9.62
+11.8%
N/A$391.24M$87.68M-17.22150
AMRN
Amarin
0.4523 of 5 stars
$19.33
+2.6%
$12.00
-37.9%
+66.0%$389.66M$228.61M-5.27360High Trading Volume
TVRD
Tvardi Therapeutics
2.8963 of 5 stars
$40.18
-0.1%
$64.25
+59.9%
N/A$377.25M$7.14M0.0080Trending News
Analyst Downgrade
Gap Down

Related Companies and Tools


This page (NASDAQ:ABOS) was last updated on 10/15/2025 by MarketBeat.com Staff
From Our Partners